Long-term persistence of treatment after hip fracture in a fracture liaison service
Abstract Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identific...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-13465-x |
| _version_ | 1811251500488327168 |
|---|---|
| author | Antonio Naranjo Amparo Molina Adrián Quevedo Francisco J. Rubiño Fernando Sánchez-Alonso Carlos Rodríguez-Lozano Soledad Ojeda |
| author_facet | Antonio Naranjo Amparo Molina Adrián Quevedo Francisco J. Rubiño Fernando Sánchez-Alonso Carlos Rodríguez-Lozano Soledad Ojeda |
| author_sort | Antonio Naranjo |
| collection | DOAJ |
| description | Abstract Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mode, previous treatment and FRAX items. Patient records were reviewed 3–8 years later, and these data were collected: (1) survival; (2) major refracture; (3) initiation of treatment, proportion of days covered (PDC) and persistence with AOM. 372 patients (mean age, 79 years; 76% women) were included. Mean follow-up was 47 months, 52 patients (14%) had a refracture (22 hip) and 129 (34.5%) died. AOM was started in 283 patients (76.0%). Factors associated with initiation of AOM were previous use of bisphosphonate (OR 9.94; 95% CI 1.29–76.32) and a lower T-score lumbar (OR 0.80; 95% CI 0.65–0.99). Persistence decreased to 72.6%, 60% and 47% at 12, 36 and 60 months. A PDC > 80% was confirmed in 208 patients (55.7%) and associated with previous use of bisphosphonate (OR 3.38; 95% CI 1.34–8.53), treatment with denosumab (OR 2.69; 95% CI:1.37–5.27), and inpatient identification (OR 2.26; 95% CI 1.18–4.34). Long-term persistence with AOM was optimal in patients with hip fracture seen at an FLS. A PDC > 80% was associated with inpatient identification and prescription of denosumab. |
| first_indexed | 2024-04-12T16:20:21Z |
| format | Article |
| id | doaj.art-cda51d74abdc4236ae64a9d7a9bbd7db |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-12T16:20:21Z |
| publishDate | 2022-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-cda51d74abdc4236ae64a9d7a9bbd7db2022-12-22T03:25:34ZengNature PortfolioScientific Reports2045-23222022-06-0112111010.1038/s41598-022-13465-xLong-term persistence of treatment after hip fracture in a fracture liaison serviceAntonio Naranjo0Amparo Molina1Adrián Quevedo2Francisco J. Rubiño3Fernando Sánchez-Alonso4Carlos Rodríguez-Lozano5Soledad Ojeda6Rheumatology Department, Hospital Universitario de Gran Canaria Dr. NegrínRheumatology Department, Hospital Universitario de Gran Canaria Dr. NegrínRheumatology Department, Hospital Universitario de Gran Canaria Dr. NegrínRheumatology Department, Hospital Universitario de Gran Canaria Dr. NegrínInvestigation Unit, Spanish Society of RheumatologyRheumatology Department, Hospital Universitario de Gran Canaria Dr. NegrínRheumatology Department, Hospital Universitario de Gran Canaria Dr. NegrínAbstract Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mode, previous treatment and FRAX items. Patient records were reviewed 3–8 years later, and these data were collected: (1) survival; (2) major refracture; (3) initiation of treatment, proportion of days covered (PDC) and persistence with AOM. 372 patients (mean age, 79 years; 76% women) were included. Mean follow-up was 47 months, 52 patients (14%) had a refracture (22 hip) and 129 (34.5%) died. AOM was started in 283 patients (76.0%). Factors associated with initiation of AOM were previous use of bisphosphonate (OR 9.94; 95% CI 1.29–76.32) and a lower T-score lumbar (OR 0.80; 95% CI 0.65–0.99). Persistence decreased to 72.6%, 60% and 47% at 12, 36 and 60 months. A PDC > 80% was confirmed in 208 patients (55.7%) and associated with previous use of bisphosphonate (OR 3.38; 95% CI 1.34–8.53), treatment with denosumab (OR 2.69; 95% CI:1.37–5.27), and inpatient identification (OR 2.26; 95% CI 1.18–4.34). Long-term persistence with AOM was optimal in patients with hip fracture seen at an FLS. A PDC > 80% was associated with inpatient identification and prescription of denosumab.https://doi.org/10.1038/s41598-022-13465-x |
| spellingShingle | Antonio Naranjo Amparo Molina Adrián Quevedo Francisco J. Rubiño Fernando Sánchez-Alonso Carlos Rodríguez-Lozano Soledad Ojeda Long-term persistence of treatment after hip fracture in a fracture liaison service Scientific Reports |
| title | Long-term persistence of treatment after hip fracture in a fracture liaison service |
| title_full | Long-term persistence of treatment after hip fracture in a fracture liaison service |
| title_fullStr | Long-term persistence of treatment after hip fracture in a fracture liaison service |
| title_full_unstemmed | Long-term persistence of treatment after hip fracture in a fracture liaison service |
| title_short | Long-term persistence of treatment after hip fracture in a fracture liaison service |
| title_sort | long term persistence of treatment after hip fracture in a fracture liaison service |
| url | https://doi.org/10.1038/s41598-022-13465-x |
| work_keys_str_mv | AT antonionaranjo longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT amparomolina longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT adrianquevedo longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT franciscojrubino longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT fernandosanchezalonso longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT carlosrodriguezlozano longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT soledadojeda longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice |